Table 1

Baseline characteristics

Patient characteristicsATG and GCSF (N = 29)ATG only (N = 29)Placebo (N = 31)
Age, years
 Mean ± SD17.2 ± 5.018.1 ± 6.916.9 ± 4.6
 Median16.415.515.0
 Range12.0–32.812.4–42.512.2–29.3
Male sex, no. of patients (%)16 (55.2)17 (58.6)17 (54.8)
Race, no. of patients (%)
 White28 (96.6)29 (100.0)29 (93.5)
 Black1 (3.4)0 (0.0)2 (6.5)
Ethnicity not Hispanic or Latino, no. of patients (%) 28 (96.6)27 (93.1)30 (96.8)
Autoantibodies positive,  no. of patients (%)
 GAD65H23 (79.3)23 (79.3)23 (74.2)
 IA2H25 (86.2)23 (79.3)25 (80.6)
 ICA*26 (92.9)25 (86.2)22 (71.0)
 ZNT821 (72.4)21 (72.4)22 (71.0)
No. of autoantibodies positive, no. of patients (%)*
 10 (0.0)3 (10.3)1 (3.2)
 23 (10.3)2 (6.9)3 (9.7)
 32 (6.9)1 (3.4)5 (16.1)
 411 (37.9)11 (37.9)13 (41.9)
 513 (44.8)12 (41.4)9 (29.0)
No. of days from diagnosis to randomization
 Median838184
 Range49–9747–10052–99
Weight, kg
 Median62.366.462.0
 Range39.8–89.139.6–92.433.8–118
BMI, kg/m2
 Median21.422.621.8
 Range16.6–27.715.2–32.814.3–34.3
AUC mean for C-peptide, nmol/L
 Mean ± SD0.793 ± 0.3210.878 ± 0.4740.966 ± 0.503
 Median0.7010.7570.932
 Range0.33 –1.780.211–2.150.144–2.08
HbA1c, %/mmol/mol
 Median7.3/567.4/577.2/55
 Range5.3–12.3/34–1114.7–9.0/28–755.5–11.2/35–99
Total daily insulin dose at baseline, units/kg*
 Median0.3390.3150.306
 Range0–1.060–0.9630–0.921
  • *Missing data: one patient missing ICA status (all four other autoantibodies positive); three patients missing baseline insulin dose.